Trends and Barriers of Medication Treatment for Opioid Use Disorders: A Systematic Review and Meta-Analysis

Abstract

Adherence to and retention in Medication Treatment for Opioid Use Disorders (MOUD) persist. We systematically reviewed trends of USA MOUD adherence, retention, and barriers from 2011–2021. Primary outcomes were adherence to and retention in MOUD, abstinence, adverse events, and treatment barriers. Effects of inverse variance random meta-analyses were examined using proportions and 95% CIs. 28 studies (102,318 patients), 78.1% male. Adherence was 56% across all studies, highest for methadone (73%). Retention by study design was heterogeneous: case series (57%), cohorts (47%), and RCTs (70%). The most common barriers were younger age, comorbid diagnoses, daily attendance, no insurance, and transportation. Abstinence was 72%, and adverse events was 5%. There was high heterogeneity in MOUD across drug types and study designs. Our findings extend the knowledge base of MOUD treatment to describe barriers that underpin the focus on retention in care above adherence given its focus to harm reduction principles.

Keywords

medications for opioid use disorders meta-analysis systematic review barriers to treatment

Get full access to this article

View all access options for this article.

References

Amiri

Lutz

Socias

M. E.

McDonell

M. G.

Roll

J. M.

Amram

(2018). Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane county Washington. Journal of Substance Abuse Treatment, 93(7), 26–30. https://doi.org/10.1016/j.jsat.2018.07.006

American Medical Association (AMA) Advocacy Resource Center . (August, 2021). Issue brief: Nation’s drug-related overdose and death epidemic continues to worsen. Updated August 4, 2021, retrieved from: https://www.ama-assn.org/system/files/issue-brief-increases-in-opioid-related-overdose.pdf

Amiri

Lutz

R. B.

McDonell

M. G.

Roll

J. M.

Amram

(2020). Spatial access to opioid treatment program and alcohol and cannabis outlets: Analysis of missed doses of methadone during the first, second, and third 90 days of treatment. The American Journal of Drug and Alcohol Abuse, 46(1), 78–87. https://doi.org/10.1080/00952990.2019.1620261

Bergeria

C. L.

Huhn

A. S.

Dunn

K. E.

(2020). The impact of naturalistic cannabis use on self-reported opioid withdrawal. Journal of Substance Abuse Treatment, 113(6), 108005. https://doi.org/10.1016/j.jsat.2020.108005

Bessaha

M. L.

Cornelius

Unick

G. J.

(2020). Barriers to behavioral health service utilization among first-generation immigrant emerging adults. Social Work in Mental Health, 18(1), 55–74. https://doi.org/10.1080/15332985.2019.1679323

Chang

Crawford

Pitts

Schein

A. Z.

Goodwin

Enggasser

J. L.

(2018). Adherence to extended release naltrexone: Patient and treatment characteristics. American Journal on Addictions, 27(6), 524–530. https://doi.org/10.1111/ajad.12786

Coker

J. L.

Catlin

Ray-Griffith

Knight

Stowe

Z. N.

(2018). Buprenorphine medication-assisted treatment during pregnancy: An exploratory factor analysis associated with adherence. Drug and Alcohol Dependence, 192(7), 146–149. https://doi.org/10.1016/j.drugalcdep.2018.07.042

Corrigan

P. W.

Druss

B. G.

Perlick

D. A.

(2014). The impact of mental illness stigma on seeking and participating in mental health care. Psychological Science in the Public Interest: A Journal of the American Psychological Society, 15(2), 37–70. https://doi.org/10.1177/1529100614531398

Cousins

S. J.

Radfar

S. R.

Crevecoeur-MacPhail

Ang

Darfler

Rawson

R. A.

(2016). Predictors of continued use of extended-released naltrexone (XR-NTX) for opioid dependence: An analysis of heroin and non-heroin opioid users in Los Angeles County. Journal of Substance Abuse Treatment, 63(12), 66–71. https://doi.org/10.1016/j.jsat.2015.12.004

10.

Daniels

A. M.

Salisbury-Afshar

Hoffberg

Agus

Fingerhood

(2014). A novel community-based buprenorphine program: Client description and initial outcomes. Journal of Addiction Medicine, 8(1), 40–46. https://doi.org/10.1097/ADM.0000000000000004

11.

Decorte

Lenton

Wilkins

(2020). Legalizing cannabis: Experiences, lessons and scenarios. Imprint Routledge.

12.

Evans

E. A.

Yoo

Huang

Saxon

A. J.

Hser

Y. I.

(2019). Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder. Journal of Substance Abuse Treatment, 106(8), 19–28. https://doi.org/10.1016/j.jsat.2019.08.002

13.

Fullerton

C. A.

Kim

Thomas

C. P.

Lyman

Montejano

L. B.

Dougherty

R. H.

Daniels

A. S.

Ghose

S. S.

Delphin-Rittmon

(2014). Medication-assisted treatment with methadone: Assessing the evidence. Psychiatric Services, 65(2), 146–157. https://doi.org/10.1176/appi.ps.201300235

14.

Gauthier

Greco

Meyers-Ohki

Desai

Rotrosen

(2021). Patients’ perspectives of initiating treatment with extended-release naltrexone (XR-NTX). Journal of Substance Abuse Treatment, 122(10), 1–8. https://doi.org/10.1016/j.jsat.2020.108183

15.

Hadland

S. E.

Wharam

J. F.

Schuster

M. A.

Zhang

Samet

J. H.

Larochelle

M. R.

(2017). Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001-2014. JAMA Pediatrics, 171(8), 747–755. https://doi.org/10.1001/jamapediatrics.2017.0745

16.

Hochheimer

Unick

G. J.

(2022). Systematic review and meta-analysis of retention in treatment using medications for opioid use disorder by medication, race/ethnicity, and gender in the United States. Addictive Behaviors, 124(10), 1–17. https://doi.org/10.1016/j.addbeh.2021.107113

17.

Hser

Y. I.

Saxon

A. J.

Huang

Hasson

Thomas

Hillhouse

Jacobs

Teruya

McLaughlin

Wiest

Cohen

Ling

(2013). Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction, 109(1), 79–87. https://doi.org/10.1111/add.12333

18.

Humphreys

Saitz

(2019). Should physicians recommend replacing opioids with cannabis? JAMA, 321(7), 639–640. https://doi.org/10.1001/jama.2019.0077

19.

Jarvis

B. P.

Holtyn

A. F.

Subramaniam

Tompkins

D. A.

Oga

E. A.

Bigelow

G. E.

Silverman

(2018). Extended-release injectable naltrexone for opioid use disorder: A systematic review. Addiction, 113(7), 1188–1209. https://doi.org/10.1111/add.14180

20.

Jones

Campopiano

Baldwin

McCance-Katz

(2015). National and state treatment need and capacity for opioid agonist medication-assisted treatment. American journal of public health, 105(8), Article e55–e63. https://doi.org/10.2105/AJPH.2015.302664

21.

Kelly

Hoppe

J. A.

Zuckerman

Khoshnoud

Sholl

Heard

(2020). A novel social work approach to emergency department buprenorphine induction and warm hand-off to community providers. The American journal of emergency medicine, 38(6), 1286–1290. https://doi.org/10.1016/j.ajem.2019.12.038

22.

Kinsky

Houck

P. R.

Mayes

Loveland

Daley

Schuster

J. M.

(2019). A comparison of adherence, outcomes, and costs among opioid use disorder medicaid patients treated with buprenorphine and methadone: A view from the payer perspective. Journal of Substance Abuse Treatment, 104(5), 15–21. https://doi.org/10.1016/j.jsat.2019.05.015

23.

Knopf

(2019). Why are methadone patients still being punished for Marijuana use? Filter. Retrieved from: https://filtermag.org/why-are-methadone-patients-still-being-punished-for-marijuana-use/

24.

Krawczyk

Maniates

Hulsey

Smith

DiDomenico

Stuart

Saloner

Bandara

(2022). Shifting medication treatment practices in the COVID-19 pandemic: A statewide survey of Pennsylvania opioid treatment programs. Journal of Addiction Medicine, 16(6), 645–652. https://doi.org/10.1097/ADM.0000000000000981

25.

Kumar

Oles

Howell

B. A.

Janmohamed

Lee

S. T.

Funaro

M. C.

O’Connor

P. G.

Alexander

(2021). The role of social network support in treatment outcomes for medication for opioid use disorder: A systematic review. Journal of Substance Abuse Treatment, 127(8), 1–9. https://doi.org/10.1016/j.jsat.2021.108367

26.

Kumari

Manalai

Leong

Wooditch

Malik

Lawson

W. B.

(2016). Factors associated with non-adherence to buprenorphine-naloxone among opioid dependent African-Americans: A retrospective chart review. American Journal on Addictions, 25(2), 110–117. https://doi.org/10.1111/ajad.12325

27.

Lagisetty

Klasa

Bush

Heisler

Chopra

Bohnert

(2017). Primary care models for treatment opioid use disorders: What actually works? A systematic review. PLoS One, 12(10), 1–40. https://doi.org/10.1371/journal.pone.0186315

28.

Lawrence

Wong

L. Y.

Grivel

M. M.

Hasin

(2017). Stigma and substance use disorders: An international phenomenon. Current Opinion in Psychiatry, 30(5), 378–388. https://doi.org/10.1097/YCO.0000000000000351

29.

Lee

C. S.

Rosales

Stein

M. D.

Nicholls

O’Connor

B. M.

Loukas Ryan

Davis

E. A.

(2019). Brief report: Low-barrier buprenorphine initiation predicts treatment retention among LatinX and non-LatinX primary care patients. American Journal on Addictions, 28(5), 409–412. https://doi.org/10.1111/ajad.12925

30.

Lincoln

Johnson

B. D.

McCarthy

Alexander

(2018). Extended-release naltrexone for opioid use disorder started during or following incarceration. Journal of Substance Abuse Treatment, 85(4), 97–100. https://doi.org/10.1016/j.jsat.2017.04.002

31.

Litz

Leslie

(2017). The impact of mental health comorbidities on adherence to buprenorphine: A claims based analysis. American Journal on Addictions, 26(8), 859–863. https://doi.org/10.1111/ajad.12644

32.

Logan

D. E.

Lavoie

A. M.

Zwick

W. R.

Kunz

Bumgardner

M. A.

Molina

(2019). Integrating addiction medicine into rural primary care: Strategies and initial outcomes. Journal of Consulting and Clinical Psychology, 87(10), 952–961. https://doi.org/10.1037/ccp0000410

33.

Bao

Y. P.

Wang

R. J.

M. F.

Liu

M. X.

J. Q.

Degenhardt

Farrell

Blow

F. C.

Ilgen

Shi

(2018). Effects of medication-assisted treatment on mortality among opioids users: A systematic review and meta-analysis. Molecular Psychiatry, 24(12), 1868–1883. https://doi.org/10.1038/s41380-018-0094-5

34.

Maglione

M. A.

Raaen

Chen

Azhar

Shahidinia

Shen

Maksabedian

Shanman

R. M.

Newberry

Hempel

(2018). Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review. Journal of Substance Abuse Treatment, 89(3), 28–51. https://doi.org/10.1016/j.jsat.2018.03.001

35.

Manhapra

Agbese

Leslie

D. L.

Rosenheck

R. A.

(2018). Three-year retention in buprenorphine treatment for opioid use disorder among privately insured adults. Psychiatric Services, 69(7), 768–776. https://doi.org/10.1176/appi.ps.201700363

36.

Martin

R. A.

Gresko

S. A.

Brinkley-Rubinstein

Stein

L. A. R.

Clarke

J. G.

(2019). Post-release treatment uptake among participants of the Rhode Island Department of Corrections comprehensive medication assisted treatment program. Preventive Medicine, 128(7), 105766. https://doi.org/10.1016/j.ypmed.2019.105766

37.

McCabe

B. E.

Santisteban

D. A.

Mena

M. P.

Duchene

D. M.

McLean

Monroe

(2013). Engagement, retention, and abstinence for three types of opioid users in Florida. Substance Use and Misuse, 48(8), 623–634. https://doi.org/10.3109/10826084.2013.800112

38.

Meacham

M. C.

Nobles

A. L.

Tompkins

D. A.

Thrul

(2022). I got a bunch of weed to help me through the withdrawals”: Naturalistic cannabis use reported in online opioid and opioid recovery community discussion forums. PLoS One, 17(2), Article e0263583. https://doi.org/10.1371/journal.pone.0263583

39.

Meinhofer

Williams

A. R.

Johnson

Schackman

B. R.

Bao

(2019). Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events? Journal of Substance Abuse Treatment, 105(7), 37–43. https://doi.org/10.1016/j.jsat.2019.07.010

40.

Montalvo

Stankiewicz

Brochier

Henderson

D. C.

Borba

C. P. C.

(2019). Long-term retention in an outpatient behavioral health clinic with buprenorphine. American Journal on Addictions, 28(5), 339–346. https://doi.org/10.1111/ajad.12896

41.

Moore

K. E.

Roberts

Reid

H. H.

Smith

K. M. Z.

Oberleitner

L. M. s.

McKee

S. A.

(2019). Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review. Journal of Substance Abuse Treatment, 99(12), 32–43. https://doi.org/10.1016/j.jsat.2018.12.003

42.

National Conference of State Legislatures . (2018). Marijuana overview. Retrieved from. https://www.ncsl.org/research/civil-and-criminal-justice/marijuana-overview.aspx

43.

National Safety Council . (2021). Safety topics: Drug overdoses. Retrieved from: https://injuryfacts.nsc.org/home-and-community/safety-topics/drugoverdoses/

44.

Noe

S. R.

Keller

(2020). Office-based buprenorphine treatment: Identifying factors that promote retention in opioid-dependent patients. Journal of Addictions Nursing, 31(1), 23–29. https://doi.org/10.1097/JAN.0000000000000320

45.

Pizzicato

L. N.

Hom

J. K.

Sun

Johnson

C. C.

Viner

K. M.

(2020). Adherence to buprenorphine: An analysis of prescription drug monitoring program data. Drug and Alcohol Dependence, 216(9), 108317. https://doi.org/10.1016/j.drugalcdep.2020.108317

46.

Ruetsch

Tkacz

Nadipelli

V. R.

Brady

B. L.

Ronquest

Volpicelli

(2017). Heterogeneity of nonadherent buprenorphine patients: Subgroup characteristics and outcomes. The American journal of managed care, 23(6), Article e172–e179. 28817294.

47.

Saloner

Daubresse

Caleb Alexander

(2017). Patterns of buprenorphine-naloxone treatment for opioid use disorder in a multistate population. Medical Care, 55(7), 669–676. https://doi.org/10.1097/mlr.0000000000000727

48.

Saloner

Krawczyk

Solomon

Allen

S. T.

Morris

Haney

Sherman

S. G.

(2022). Experiences with substance use disorder treatment during the COVID-19 pandemic: Findings from a multistate survey. International Journal of Drug Policy, 101(10), 103537. https://doi.org/10.1016/j.drugpo.2021.103537

49.

Samples

Williams

A. R.

Olfson

Crystal

(2018). Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. Journal of Substance Abuse Treatment, 95(1), 9–17. https://doi.org/10.1016/j.jsat.2018.09.001

50.

Schneider

K. E.

Allen

S. T.

Rouhani

Morris

Haney

Saloner

Sherman

S. G.

(2022). Increased solitary drug use during COVID-19: An unintended consequence of social distancing. International Journal of Drug Policy, 111(10), 103923. https://doi.org/10.1016/j.drugpo.2022.103923

51.

Schomerus

Lucht

Holzinger

Matschinger

Carta

M. G.

Angermeyer

M. C.

(2011). The stigma of alcohol dependence compared with other mental disorders: A review of population studies. Alcohol and Alcoholism, 46(2), 105–112. https://doi.org/10.1093/alcalc/agq089

52.

Schwartz

R. P.

Kelly

S. M.

O’Grady

K. E.

Gandhi

Jaffe

J. H.

(2011). Randomized trial of standard methadone treatment compared to initiating methadone without counseling: 12-month findings. Addiction, 107(5), 943–952. https://doi.org/10.1111/j.1360-0443.2011.03700.x

53.

Scott

C. K.

Dennis

M. L.

Grella

C. E.

Kurz

Sumpter

Nicholson

Funk

R. R.

(2020). A community outreach intervention to link individuals with opioid use disorders to medication-assisted treatment. Journal of Substance Abuse Treatment, 108(7), 75–81. https://doi.org/10.1016/j.jsat.2019.07.001

54.

Shover

C. L.

Vest

N. A.

Chen

Stueber

Falasinnu

T. O.

Hah

J. M.

Kim

Mackey

Weber

K. A.

2nd Ziadni

Humphreys

(2020). Association of state policies allowing medical cannabis for opioid use disorder with dispensary marketing for this indication. JAMA Network Open, 3(7), Article e2010001. https://doi.org/10.1001/jamanetworkopen.2020.10001

55.

Sprague Martinez

Walter

A. W.

Acevedo

López

L. M.

Lundgren

(2018). Context matters: Health disparities in substance use disorders and treatment. Journal of Social Work Practice in the Addictions, 18(1), 84–98. https://doi.org/10.1080/1533256x.2017.1412979

56.

Teruya

Schwartz

R. P.

Mitchell

S. G.

Hasson

A. L.

Thomas

Buoncristiani

S. H.

Hser

Wiest

Cohen

A. J.

Glick

Jacobs

McLaughlin

Ling

(2014). Patient perspectives on buprenorphine/naloxone: A qualitative study of retention during the starting treatment with agonist replacement therapies (start) study. Journal of Psychoactive Drugs, 46(5), 412–426. https://doi.org/10.1080/02791072.2014.921743

57.

Thomas

C. P.

Fullerton

C. A.

Kim

Montejano

Lyman

Dougherty

R. H.

Daniels

A. S.

Ghose

S. S.

Delphin-Rittmon

M. E.

(2014). Medication-assisted treatment with buprenorphine: Assessing the evidence. Psychiatric Services, 65(2), 158–170. https://doi.org/10.1176/appi.ps.201300256

58.

Tkacz

Severt

Cacciola

Ruetsch

(2011). Compliance with buprenorphine medication-assisted treatment and relapse to opioid use. American Journal on Addictions, 21(1), 55–62. https://doi.org/10.1111/j.1521-0391.2011.00186.x

59.

Tran

B. X.

Nguyen

L. H.

Tran

T. T.

Latkin

C. A.

(2018). Social and structural barriers for adherence to methadone maintenance treatment among Vietnamese opioid dependence patients. PLoS One, 13(1), Article e0190941. https://doi.org/10.1371/journal.pone.0190941

60.

US Department of Health and Human Services , Office of Inspector General. (2020). Geographic disparities affect access to buprenorphine services for opioid use disorder. Retrieved from https://oig.hhs.gov/oei/reports/oei-12-17-00240.asp

61.

Weintraub

Greenblatt

A. D.

Chang

Himelhoch

Welsh

(2018). Expanding access to buprenorphine treatment in rural areas with the use of telemedicine. The American Journal on Addictions, 27(8), 612–617. https://doi.org/10.1111/ajad.12805

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.69 MB